Application of a kind of prothrombin mutant protein and its coding nucleic acid

A prothrombin mutation and encoding nucleic acid technology, which is applied to peptide/protein components, medical preparations containing active ingredients, enzymes, etc., can solve problems such as limiting the hemostatic effect, weakening the hemostatic effect of prothrombin, and unsatisfactory effects , to achieve the effect of improving blood coagulation function, good treatment prospect and high promoting effect
CN109260462BActive Publication Date: 2021-05-11RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +3
7 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Publication Date
2021-05-11

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the application of a prothrombin mutant protein and its coding nucleic acid for preparing gene therapy medicine, including linking it with a promoter and / or termination sequence and constructing an expression plasmid. The mutant protein and its encoding nucleic acid of the present invention have high blood coagulation activity, can efficiently promote blood coagulation, improve the overall blood coagulation function of the body, and have good prospects for gene therapy, gene editing and recombinant protein replacement therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The invention belongs to the field of bleeding treatment, and in particular, the present invention relates to a prothrombin mutant protein and its encoding nucleic acid.Background technique

[0002] Coagulation factor defects or other human coagulation dysfunction can result in hemorrhagic diseases, in which hemorrhagic diseases (A -1 / B) due to blood-bleeding disease caused by coagulation factor VIII / IX (FVII / FIX) defects , Severe patients' coagulation factor VIII / IX activity is often less than 1% of normal, often spontaneous bleeding results in muscle hematoma or articulation. Infusion factor VIII / IX preparation (currently usually a thirty-expression of thromboplane VIII / IX protein) supplemented with the patient's body is the only effective treatment, but frequent administration is required. Genetic therapy is currently in the treatment of clinical trials, and introduces normal coagulation factor VIII / IX gene into patients, thereby achieving improving...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More